Gadolinium is the rare earth element with the most distinctive demand profile in the REE basket: its largest single end use — gadolinium-based MRI contrast agents (GBCAs) consumed in roughly 25–35% of all MRI procedures globally — has no direct analog among the light rare earths that dominate REE basket economics. USGS MCS 2025 reports 2024 world REE production at 390,000 t REO, implying approximately 3,900 tonnes of Gd2O3 at a ~1.0% basket share (highly uncertain; actual Gd% ranges from <0.2% in bastnaesite to 2–5% in ion adsorption clay deposits). X-ray and CT scintillator phosphors (Gd2O2S:Tb, "GOS"), NdFeB magnet additives for high-temperature coercivity stability, and nuclear reactor burnable absorbers account for most of the remaining demand. Gd's exceptional thermal neutron capture cross-section (~258,000 barns for Gd-157) underpins both nuclear fuel management and neutron-shielding applications.

Supply is structurally dependent on China's ion adsorption clay sector. While China accounts for ~69% of world REO mining, its actual contribution to gadolinium supply is likely higher because southern Chinese deposits are enriched in heavy rare earths including Gd, in contrast to the LREE-dominant bastnaesite mines in the US and Australia. China controls approximately 90% of global REE separation and refining capacity, meaning essentially all pharmaceutical-grade Gd2O3 for GBCA manufacturing flows through Chinese refineries before reaching pharmaceutical companies in Europe, Japan, and North America. Myanmar and Thailand — which together contributed ~11% of world REO output in 2024 — also produce from HREE-enriched ion adsorption clays processed into Chinese supply chains via concentrate exports.

The strategic calculus around gadolinium shifted abruptly in April 2025 when China announced export licensing controls covering Gd and six other heavy rare earth elements, targeting elements critical for defense systems, advanced medical imaging, and clean energy technology. Both the EU and US have designated REEs (including heavy REEs such as Gd) as critical and strategic materials under the EU Critical Raw Materials Act (Regulation 2024/1252) and the US 2022 Critical Minerals List respectively. Unlike lanthanum and cerium — which suffer from chronic oversupply and near-floor prices (~$1/kg oxide) — gadolinium commands a meaningful price premium reflecting its HREE scarcity and end-use specificity in medical and defense applications. The combination of single-country supply concentration, specialized pharmaceutical-grade purity requirements, and inelastic MRI contrast demand makes Gd one of the more acute supply security risks within the REE basket.